New Areas of Interest: Is There a Role for Omega-3 Fatty Acid Supplementation in Patients With Diabetes and Cardiovascular Disease?
Purpose of Review
Summarize studies on omega-3 fatty acids in prevention of albuminuria in subjects with diabetes.
Several small, short-term trials suggested benefit on albuminuria in subjects with diabetes; however, results were not definitive. Welty et al. showed that eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 1 year slowed progression of early-stage albuminuria in subjects with diabetes with clinical coronary artery disease on an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, the majority of whom had an albumin/creatinine ratio (ACR) < 30 μg/mg. Moreover, significantly more (3-fold) subjects on EPA and DHA had a decrease in ACR compared to control, and three on EPA and DHA had a change in category from > 30 μg/mg to < 30 μg/mg, whereas no controls did. Potential mechanisms for benefit are discussed.
These results suggest that there is benefit and perhaps even reversal of albuminuria with EPA and DHA at an early stage of disease in those with ACR < 30 μg/mg and those with microalbuminuria (ACR > 30).
KeywordsOmega-3 fatty acids Diabetes Albuminuria Coronary artery disease Eicosapentaenoic acid Docosahexaenoic acid
Compliance with Ethical Standards
Conflict of Interest
The author declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Keen H, Chlouverakis C, Fuller J, Jarrett RJ. The concomitants of raised blood sugar: studies in newly-detected hyperglycemics II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guys Hospital Reports. 1969;118:247–54.Google Scholar
- 7.Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617–24.CrossRefGoogle Scholar
- 13.Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey Lancet. 1998;2:530–3.Google Scholar
- 16.Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33:189–98.CrossRefGoogle Scholar
- 20.•• Sung KC, Ryu S, Lee JY, Lee SH, Cheong E, Hyun YY, et al. Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. J Am Heart Assoc. 2016;5(9):e003245. https://doi.org/10.1161/JAHA.116.003245. Urine albumin to creatinine ratio (ACR) < 30 μg/mg, which has generally been considered in the normal range, predicted incident hypertension and cardiovascular disease mortality at 11-year follow-up in subjects who were healthy and nondiabetic at baseline. CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRefGoogle Scholar
- 28.•• Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diab Endocrinol. 2015;3:514–25. The Chronic Kidney Disease Prognosis Consortium reported that an increase in urine albumin excretion as low as 10 μg/ml is associated with an increased risk of cardiovascular disease, end-stage renal disease and mortality in the general population and among those with kidney disease, a finding highlighting the need for studies targeting albuminuria as a risk factor. CrossRefGoogle Scholar
- 36.Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202.CrossRefGoogle Scholar
- 42.•• Fukami A, Adachi H, Hirai Y, Enomoto M, Otsuka M, Kumagai E, et al. Association of serum eicosapentaenoic acid to arachidonic acid ratio with microalbuminuria in a population of community-dwelling Japanese. Atherosclerosis. 2015;239(2):577–82. https://doi.org/10.1016/j.atherosclerosis.2015.02.033. In a prospective study of 444 Japanese subjects, those with a low EPA/arachidonic acid (AA) ratio had a 3.45-fold higher odds ratio of microalbuminuria (ACR ≥ 30 mg/g Cr) after adjustment for confounding factors. This finding suggests that the ratio of pro-resolving to pro-inflammatory fatty acids is important in determining progression of albuminuria. CrossRefPubMedGoogle Scholar
- 43.• Han E, Yun Y, Kim G, Lee YH, Wang HJ, Lee BW, et al. Effects of omega-3 fatty acid supplementation on diabetic nephropathy progression in patients with diabetes and hypertriglyceridemia. PLoS One. 2016;11(5):e0154683. https://doi.org/10.1371/journal.pone.0154683 eCollection 2016. In this retrospective study of subjects with type 2 DM who received omega-3 FAs to manage hypertriglyceridemia, those receiving 4 g/day of omega-3 FAs had a reduction in albuminuria after adjustment for multiple variables ( p < 0.001). CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Miller ER III, Juraschek SP, Anderson CA, Guallar E, Henoch-Ryugo K, Charleston J, et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36:1462–9.CrossRefGoogle Scholar
- 51.•• Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK. Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes and coronary artery disease. J Am Heart Assoc. 2017;6:e004740. https://doi.org/10.1161/JAHA.116.004740. A randomized, parallel, controlled 1-year trial which showed that high-dose EPA and DHA prevented progression of albuminuria in subjects with diabetes and coronary artery disease. CrossRefPubMedPubMedCentralGoogle Scholar
- 53.• Al Faddagh A, Elajami TK, Ashfaque H, Saleh M, Bistrian B, Welty FK. Effect of eicosapentaenoic and docosahexaenoic acids on coronary artery plaque: a randomized controlled trial. J Am Heart Assoc. 2017;6:e006981. https://doi.org/10.1161/JAHA.117.006981. A randomized, parallel, controlled 1-year trial which showed that high-dose EPA and DHA prevented progression of coronary artery plaque in subjects with coronary artery disease. CrossRefGoogle Scholar
- 59.An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation and tubulointerstitial fibrosis in the remnant kidney. Am J Phys. 2009;297(4):F895–eF903.Google Scholar
- 60.Kumar V, Abbas AK, Aster JC. Inflammation and repair. In: Kumar V, Abbas AK, Aster JC, editors. Robbins and Cotran pathologic basis of disease. 9th ed. Philadelphia: Elsevier/Saunders; 2015. p. 69–111.Google Scholar
- 73.•• Mas E, Barden A, Burke V, Beilin LJ, Watts GF, Huang RC, et al. A randomized control trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin Nutr. 2015;35(2):331–6. A randomized trial which reported that omega-3 fatty acids increase plasma levels of their downstream products, resolvins, which actively terminate chronic inflammation, in subjects with chronic kidney disease.CrossRefGoogle Scholar